TQ treatment (2, 5, and 10 mg/kg for 3 weeks, IP) modified inflammatory-induced liver fibrosis by affecting oxidant/anti-oxidant balance (reduced MDA and increased activity of SOD and CAT enzymes) (91). The gene discussed is SOD1; the disease is Hepatic fibrosis.